Catrin H. Middleton
Serum autoantibody measurement for the detection of hepatocellular carcinoma
Middleton, Catrin H.; Irving, William; Robertson, John F.R.; Murray, Andrea; Parsy-Kowalska, Celine B.; Macdonald, Isabel K.; McElveen, Jane; Allen, Jared; Healey, Graham F.; Ryder, Stephen J.; Holdenrieder, Stefan; Chapman, Caroline J.; Thomson, Brian J.
Authors
William Irving
JOHN ROBERTSON john.robertson@nottingham.ac.uk
Professor of Surgery
Andrea Murray
Celine B. Parsy-Kowalska
Isabel K. Macdonald
Jane McElveen
Jared Allen
Graham F. Healey
Stephen J. Ryder
Stefan Holdenrieder
Caroline J. Chapman
Brian J. Thomson
Abstract
Background: Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate screening tests largely account for presentation of advanced tumours and high mortality rates. Early detection of HCC amongst high-risk groups is paramount in improving prognosis. This research aimed to further characterise the previously described humoral immune response raised to tumour-associated antigens (TAAs) in the serum of patients with HCC.
Methods: Serum from 96 patients with confirmed HCC, 96 healthy controls matched for age and sex, 78 patients with confirmed liver cirrhosis and 91 patients with confirmed chronic liver disease were analysed for the presence of IgG autoantibodies raised to 41 recombinant TAAs/antigen fragments by ELISA.
Results: Varying autoantibody specificities (97–100%) and sensitivities (0–10%) were observed to individual TAAs. A 21-
antigen panel achieved a specificity of 92% and sensitivity of 45% for the detection of HCC. This same panel identified 21% of 169 high-risk controls as having elevated autoantibody levels. A reproducible panel of 10 antigens achieved a specificity of 91% and sensitivity of 41% in HCC. 15% of 152 high-risk controls gave positive results with this panel.
Conclusions: This minimally invasive blood test has the potential to offer advantages over currently available tools for the identification of HCC amongst pre-disposed patients. Results are comparable to current gold standards in HCC (Ultrasonography) and to similar tests in other cancers (EarlyCDT-Lung).
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 2, 2014 |
Online Publication Date | Aug 5, 2014 |
Publication Date | Aug 5, 2014 |
Deposit Date | Sep 5, 2017 |
Publicly Available Date | Apr 12, 2019 |
Journal | PLoS ONE |
Electronic ISSN | 1932-6203 |
Publisher | Public Library of Science |
Peer Reviewed | Peer Reviewed |
Volume | 9 |
Issue | 8 |
Article Number | e103867 |
Pages | 1-9 |
DOI | https://doi.org/10.1371/journal.pone.0103867 |
Public URL | https://nottingham-repository.worktribe.com/output/1118375 |
Publisher URL | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103867 |
PMID | 25093332 |
Files
Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma
(331 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?
(2016)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search